{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T07:13:37Z","timestamp":1772003617456,"version":"3.50.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Pfizer Inc., New York, NY, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s13555-025-01618-5","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T02:10:47Z","timestamp":1766110247000},"page":"789-806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tailoring Abrocitinib Treatment for Moderate-to-Severe Atopic Dermatitis to Patient Disease Course: A Narrative Review"],"prefix":"10.1007","volume":"16","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Weidinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melissa","family":"Watkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-1675","authenticated-orcid":false,"given":"Justine","family":"Alderfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,19]]},"reference":[{"issue":"10247","key":"1618_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"2","key":"1618_CR2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.5021\/ad.2010.22.2.125","volume":"22","author":"T Bieber","year":"2010","unstructured":"Bieber T. Atopic dermatitis. Ann Dermatol. 2010;22(2):125\u201337.","journal-title":"Ann Dermatol"},{"issue":"2","key":"1618_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.36849\/JDD.6408","volume":"21","author":"R Chovatiya","year":"2022","unstructured":"Chovatiya R, Silverberg JI. The heterogeneity of atopic dermatitis. J Drugs Dermatol. 2022;21(2):172\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"1618_CR4","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.jaad.2018.09.035","volume":"80","author":"YW Yew","year":"2019","unstructured":"Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390\u2013401.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1618_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.det.2017.02.003","volume":"35","author":"K Abuabara","year":"2017","unstructured":"Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35(3):291\u20137.","journal-title":"Dermatol Clin"},{"issue":"1","key":"1618_CR6","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/all.13946","volume":"75","author":"N Stefanovic","year":"2020","unstructured":"Stefanovic N, Flohr C, Irvine AD. The exposome in atopic dermatitis. Allergy. 2020;75(1):63\u201374.","journal-title":"Allergy"},{"issue":"3","key":"1618_CR7","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1007\/s40521-021-00289-9","volume":"8","author":"N Stefanovic","year":"2021","unstructured":"Stefanovic N, Irvine AD, Flohr C. The role of the environment and exposome in atopic dermatitis. Curr Treat Options Allergy. 2021;8(3):222\u201341.","journal-title":"Curr Treat Options Allergy"},{"issue":"5","key":"1618_CR8","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.anai.2020.06.014","volume":"125","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Lei D, Yousaf M, et\u00a0al. Association of itch triggers with atopic dermatitis severity and course in adults. Ann Allergy Asthma Immunol. 2020;125(5):552-9.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1618_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2500\/aap.2017.38.4005","volume":"38","author":"AM Drucker","year":"2017","unstructured":"Drucker AM. Atopic dermatitis: burden of illness, quality of life, and associated complications. Allergy Asthma Proc. 2017;38(1):3\u20138.","journal-title":"Allergy Asthma Proc"},{"issue":"6","key":"1618_CR10","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.anai.2020.07.005","volume":"125","author":"MR Hong","year":"2020","unstructured":"Hong MR, Lei D, Yousaf M, et\u00a0al. A real-world study of the longitudinal course of adult atopic dermatitis severity in clinical practice. Ann Allergy Asthma Immunol. 2020;125(6):686-92.e3.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1618_CR11","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","volume":"120","author":"M Boguniewicz","year":"2018","unstructured":"Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22.e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"1618_CR12","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1111\/jdv.20095","volume":"38","author":"JP Thyssen","year":"2024","unstructured":"Thyssen JP, Silverberg JI, Ruano J, et\u00a0al. Optimizing maintenance therapy in responders to abrocitinib induction: a post hoc analysis of JADE REGIMEN. J Eur Acad Dermatol Venereol. 2024;38(11):2130\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1618_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, et\u00a0al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1618_CR14","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1007\/s13555-023-00948-6","volume":"13","author":"MJ Gooderham","year":"2023","unstructured":"Gooderham MJ, Pink AE, Simpson EL, Silverberg JI, G\u00fcler E, Watkins M. Abrocitinib 100 mg once daily for moderate-to-severe atopic dermatitis: a review of efficacy and safety, and expert opinion on use in clinical practice. Dermatol Ther (Heidelb). 2023;13(9):1893\u2013907.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1618_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2024.09.022","volume":"134","author":"T Bieber","year":"2025","unstructured":"Bieber T. The paradigm shift in drug development for atopic dermatitis: addressing the variables of the equation leading to disease modification. Ann Allergy Asthma Immunol. 2025;134(2):144\u201350.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"1618_CR16","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00403-021-02321-z","volume":"315","author":"LEM de Wijs","year":"2022","unstructured":"de Wijs LEM, van Egmond S, Devillers ACA, Nijsten T, Hijnen D, Lugtenberg M. Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study. Arch Dermatol Res. 2022;315(1):75\u201383.","journal-title":"Arch Dermatol Res"},{"key":"1618_CR17","unstructured":"Cibinqo (abrocitinib). Prescriber brochure. Pfizer Labs.; 2023."},{"key":"1618_CR18","unstructured":"Cibinqo 50 mg film-coated tablets. Summary of product characteristics. Pfizer Europe MA EEIG; 2022."},{"key":"1618_CR19","unstructured":"Cibinqo (abrocitinib). Product monograph including patient medication information. Pfizer Canada ULC.; 2022."},{"key":"1618_CR20","unstructured":"Cibinqo 100 mg film-coated tablets. Summary of product characteristics. Pfizer Limited; 2021."},{"key":"1618_CR21","unstructured":"Cibinqo (abrocitinib) tablets. Product information. Pfizer Australia Pty Ltd.; 2025."},{"key":"1618_CR22","unstructured":"Cibinqo (abrocitinib) tablets, for oral use. Prescribing information. Pfizer Investment Co., Ltd.; 2022."},{"key":"1618_CR23","unstructured":"Cibinqo (abrocitinib) tablets, for oral use 50 mg 100 mg 200 mg. Prescribing information. Pfizer Japan Inc.; 2021."},{"issue":"12","key":"1618_CR24","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, et\u00a0al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"1618_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, et\u00a0al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366.","journal-title":"Lancet"},{"issue":"8","key":"1618_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et\u00a0al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1618_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et\u00a0al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"10348","key":"1618_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, et\u00a0al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382.","journal-title":"Lancet"},{"issue":"10","key":"1618_CR29","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, et\u00a0al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373.","journal-title":"JAMA Dermatol"},{"key":"1618_CR30","unstructured":"Silverberg JI, Blauvelt A, Simpson EL, et\u00a0al. Identifying patient subgroups with comparable benefit from continuous versus reduced abrocitinib maintenance doses in JADE REGIMEN. Presented at: 3rd Annual RAD Virtual Conference; December 11\u201313, 2021; Virtual."},{"issue":"7","key":"1618_CR31","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1007\/s13555-024-01183-3","volume":"14","author":"AW Armstrong","year":"2024","unstructured":"Armstrong AW, Alexis AF, Blauvelt A, et\u00a0al. Predicting abrocitinib efficacy at week 12 based on clinical response at week 4: a post hoc analysis of four randomized studies in moderate-to-severe atopic dermatitis. Dermatol Ther Heidelb. 2024;14(7):1849\u201361.","journal-title":"Dermatol Ther Heidelb"},{"issue":"2","key":"1618_CR32","volume":"7","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Boguniewicz M, Papp K, et\u00a0al. Efficacy of abrocitinib rescue therapy in the phase 3 study JADE REGIMEN. J Cutan Med Surg. 2023;7(2):s152.","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"1618_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.12.076","volume":"149","author":"J Silverberg","year":"2022","unstructured":"Silverberg J, Boguniewicz M, Papp K, et\u00a0al. Efficacy of abrocitinib rescue therapy in the phase 3 study JADE REGIMEN. J Allergy Clin Immunol. 2022;149(2):AB11.","journal-title":"J Allergy Clin Immunol"},{"key":"1618_CR34","doi-asserted-by":"crossref","unstructured":"Silverberg JI, Simpson EL, Gooderham MJ, et\u00a0al. Efficacy of step-up abrocitinib treatment in combination with topical medicated therapy for treating atopic dermatitis flares: a post hoc analysis of the JADE REGIMEN trial. Presented at: American Academy of Dermatology (AAD) Annual Meeting; March 8\u201312, 2024; San Diego, CA.","DOI":"10.1016\/j.jaad.2024.07.160"},{"issue":"5","key":"1618_CR35","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et\u00a0al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1618_CR36","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s40257-024-00869-w","volume":"25","author":"EL Simpson","year":"2024","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, et\u00a0al. Integrated safety update of abrocitinib in 3802 patients with moderate-to-severe atopic dermatitis: data from more than 5200 patient-years with up to 4 years of exposure. Am J Clin Dermatol. 2024;25(4):639\u201354.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"1618_CR37","doi-asserted-by":"publisher","first-page":"AB116","DOI":"10.1016\/j.jaad.2023.07.466","volume":"89","author":"K Reich","year":"2023","unstructured":"Reich K, Silverberg JI, de Bruin-Weller M, et\u00a0al. Abrocitinib long-term efficacy for up to 96 weeks in patients with moderate-to-severe atopic dermatitis: interim analysis of JADE EXTEND, a long-term extension study. J Am Acad Dermatol. 2023;89(3):AB116.","journal-title":"J Am Acad Dermatol"},{"key":"1618_CR38","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et\u00a0al. Evaluating the flexibility of abrocitinib: treating flares with step-up and step-down therapy. Presented at 25th World Congress of Dermatology; 3\u20138 July 2023; Singapore."},{"key":"1618_CR39","unstructured":"Simpson EL, Weidinger S, Irvine AD, et\u00a0al. Long-term safety of flexible abrocitinib dosing in patients with moderate to severe atopic dermatitis with up to 4.1 years of exposure and efficacy at 96 weeks of treatment: an interim analysis of JADE EXTEND. Presented at 33rd Annual European Academy of Dermatology and Venereology (EADV) Congress; 25\u201328 September 2024; Amsterdam, the Netherlands."},{"key":"1618_CR40","unstructured":"Simpson EL, Gutermuth J, Maurer M, et\u00a0al. Integrated safety analysis of abrocitinib in 3848 patients with moderate-to-severe atopic dermatitis: data from more than 7000 patient-years with up to ~4.5 years of exposure. Presented at European Academy of Allergy and Clinical Immunology Congress; 31 May\u20133 June 2024; Valencia, Spain."},{"issue":"1","key":"1618_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2023.2200866","volume":"34","author":"C Flohr","year":"2023","unstructured":"Flohr C, Cork MJ, Ardern-Jones MR, et\u00a0al. Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial. J Dermatol Treat. 2023;34(1):2200866.","journal-title":"J Dermatol Treat"},{"issue":"8","key":"1618_CR42","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1111\/all.16512","volume":"80","author":"AS Paller","year":"2025","unstructured":"Paller AS, Eichenfield LF, Irvine AD, et\u00a0al. Integrated efficacy and safety analysis of abrocitinib in adolescents with moderate-to-severe atopic dermatitis. Allergy. 2025;80(8):2213\u201324.","journal-title":"Allergy"},{"issue":"4","key":"1618_CR43","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1002\/jvc2.203","volume":"2","author":"MJ Gooderham","year":"2023","unstructured":"Gooderham MJ, Ardern-Jones MR, Guttman-Yassky E, et\u00a0al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis with prior exposure to oral systemic immunosuppressants or biologic therapies: a post hoc analysis of the JADE clinical trials. JEADV Clin Pract. 2023;2(4):753\u201363.","journal-title":"JEADV Clin Pract"},{"key":"1618_CR44","doi-asserted-by":"crossref","unstructured":"Guttman-Yassky E, Gooderham M, Ardern-Jones MR, et\u00a0al. Efficacy of abrocitinib in patients based on prior biologic treatment history: a post hoc analysis of JADE MONO-1, JADE MONO-2, and JADE REGIMEN. Presented at American Academy of Dermatology (AAD) Annual Meeting; 7\u201311 March 2025; Orlando, FL.","DOI":"10.1016\/j.jaad.2025.05.754"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01618-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01618-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T06:40:29Z","timestamp":1772001629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01618-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,19]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01618-5","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,19]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jonathan I. Silverberg has served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; and as a speaker for Regeneron Pharmaceuticals and Sanofi Genzyme. Eric Simpson has received grants from Pfizer Inc., Eli Lilly and Company, Kyowa Kirin, LEO Pharma, Merck, and Regeneron and personal fees from Pfizer Inc., Bausch Health (Valeant), Dermira, Eli Lilly and Company, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron, and Sanofi Genzyme. Melinda Gooderham has received grants, personal fees, honoraria, and\/or nonfinancial support from Pfizer Inc., AbbVie, Amgen, AkrosPharma, Arcutis, AnaptysBio, Aristea, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Dermavant, Dermira, Eli Lilly and Company, Galderma, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Merck, Moonlake, Meiji, Nektar, Novartis, Roche, Sanofi Genzyme, Regeneron Pharmaceuticals, Sun Pharma, UCB, Ventyx, and Bausch Health. Stephan Weidinger has received institutional research grants from La Roche-Posay, LEO Pharma, and Sanofi Deutschland GmbH; has performed consultancies for Pfizer Inc., AbbVie, Eli Lilly and Company, Kymab, LEO Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; has lectured at educational events sponsored by AbbVie, Galderma, LEO Pharma, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme; and is involved in performing clinical trials with many pharmaceutical industries that manufacture drugs used for the treatment of psoriasis and atopic dermatitis. Melissa Watkins and Justine Alderfer are employees and shareholders of Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}